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Abstract The ability of the Breast and Ovarian Analysis
of Disease Incidence and Carrier Estimation Algorithm
(BOADICEA) model to predict BRCA1 and BRCA2
mutations and breast cancer incidence in women with a
family history of breast cancer was evaluated. Observed
mutations in 263 screened families were compared to ret-
rospective predictions. Similarly, observed breast cancers
in 640 women were compared to retrospective predictions
of breast cancer incidence. The ratios of observed to
expected number of BRCA1-,BRCA2- and BRCA(1 or 2)
mutations were 1.43 (95% CI 1.05–1.90), 0.63 (95% CI
0.34–1.08), and 1.12 (95% CI 0.86–1.44), showing a sig-
niﬁcant underestimation of BRCA1 mutations. Discrimi-
nation between carriers and non-carriers as measured by
area under the receiver operating characteristic (ROC)
curve was 0.83 (95% CI 0.76–0.88). The ratio of observed
to expected number of invasive breast cancers was 1.41
(0.91–2.08). The corresponding area under the ROC curve
for prediction of invasive breast cancer at individual level
was 0.62 (95% CI 0.52–0.73). In conclusion, the BO-
ADICEA model can predict the total prevalence of
BRCA(1 or 2) mutations and the incidence of invasive
breast cancers. The mutation probability as generated by
BOADICEA can be used clinically as a guideline for
screening, and thus decrease the proportion of negative
mutation analyses. Likewise, individual breast cancer risks
can be used for selecting women whose risk of breast
cancer indicates follow-up. Application of local mutation
frequencies of BRCA1 and BRCA2 could improve the
ability to distinguish between the two genes.
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Introduction
Womenwithafamilyhistoryofbreast-and/orovariancancer,
earlyage atbreastcanceronset ormen withbreastcancercan
be referred for genetic counselling. The procedure involves
investigation of family history, if indicated, BRCA1 and
BRCA2mutationscreeningandestimationofandinformation
on cancer risk. A personal risk-reducing strategy might be
recommended,suchasincreasedsurveillance orprophylactic
surgery. It is important for patients and caregivers alike, that
the separation of high risk individuals, eligible for follow-up
action, from individuals with population risk, is as sensitive
and speciﬁc as possible.
A number of risk assessment tools for familial breast-
and ovarian cancer have been described. These include the
Claus model [1–3], the BRCAPRO computer program [4]
and web-based programs such as IBIS [5] and the Breast
and Ovarian Analysis of Disease Incidence and Carrier
Estimation Algorithm (BOADICEA) [6, 7].
BOADICEA is used in Swedish cancer genetic clinics. It
was developed using women/families mainly from the UK
but also including a few families from other countries,
among them Sweden [8].
BOADICEA’s prediction of BRCA1 and BRCA2 muta-
tions in different populations has been investigated in
several studies [9–13] and found to perform similarly or
better than other risk assessment tools. The frequencies of
BRCA1 and BRCA2 mutations in Sweden are likely to
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presence of several BRCA1 founder mutations. Thus, a
need to evaluate the model in Swedish women was iden-
tiﬁed. Regarding breast cancer risk, BOADICEA accu-
rately predicted the age-speciﬁc familial relative risk
(FRR) for an individual with an affected mother, when
compared to the observed FRR in epidemiological studies
[7]. To our knowledge, no studies of the model’s ability to
predict breast cancer in a speciﬁed group of women rep-
resented by extended pedigrees have been published. The
model was developed for invasive breast cancer [6, 7] and
the program’s homepage [14] states that the accuracy of the
program is less clear for ductal cancer in situ (DCIS).
Consequently there was also a need to investigate the effect
of including DCIS diagnoses in the calculations.
The present aims were to investigate BOADICEA’s
ability to predict BRCA1 and BRCA2 mutations, and its
ability to predict breast cancer within a speciﬁed observa-
tion period, in a cohort of Swedish women.
Methods
Study material
The material consisted of pedigrees and medical records
belonging to 652 women (index persons) who consecu-
tively attended the cancer genetic clinic for hereditary
breast- and ovarian cancer at any of three hospitals in
Stockholm (Karolinska University Hospital, So ¨dersjukhu-
set, Danderyd Hospital) during January 2002 to June 2006.
The women had been assigned at least 17% life time risk
for breast cancer using Claus tables which is an almost
doubled risk compared to the general population. They also
fulﬁlled age criteria for being eligible for annual breast
imaging (mammography ± ultrasound). Earliest age for
initializing breast controls was either 10 years before the
youngest age of breast cancer onset in respective family, or
from 25 years of age in families with a known BRCA1 or
BRCA2 mutation. Highest age was 60 years. Furthermore,
individuals with an identiﬁed mutation other than in
BRCA1 or BRCA2 were not included. Women with a per-
sonal history of ovarian cancer before start of observation
were not included in the breast cancer risk prediction study
but her pedigree could be included in the study of mutation
risk predictions. All 652 women had had a normal mam-
mogram within 1 year before the start of observation in
order to avoid inclusion of women with a current breast
cancer. Most of the women had been included in a pro-
spective study on breast cancer diagnostic methods
(PSDM) including mammography, ultrasound and, in the
case of BRCA1 or BRCA2 mutation carriers, breast mag-
netic resonance imaging. The design and result of that
study will be presented elsewhere. Pedigrees provided
information about cancer diagnoses veriﬁed through med-
ical records and/or death certiﬁcates, age at cancer onset,
year of birth for affected individuals with a cancer diag-
nosis, and screening status for BRCA1 and BRCA2.
Mutation screening on genomic DNA had been offered
in families fulﬁlling the clinical criteria regarding family
history of breast- and/or ovarian cancer [15]. The pre-
screening techniques protein truncation test and denatur-
izing high-performance liquid chromatography (WAVE
DNA Fragment Analysis System, Transgenomic Inc., San
Jose, CA, USA) were used in combination with direct
sequencing and multiplex ligation-dependent probe
ampliﬁcation (MLPA, MRC Holland, The Netherlands). If
no fresh material was available, genomic DNA was
extracted from parafﬁn-embedded tissue and analyzed
using the Sequenom MassARRAY system (Sequenom, San
Diego, CA, USA) or the pyrosequencing PSQ HS96 system
(Biotage AB, Uppsala, Sweden). All mutation analyses
were performed at Lund University Hospital.
A minor proportion of cancer diagnoses had not been
veriﬁed from medical records due to insufﬁcient data.
These diagnoses were included if diagnosis as well as age
at onset were considered reliable by the oncologist per-
forming the family-history investigation. Most pedigrees
covered four generations including siblings and offspring
in each. Year of birth was sometimes noted but not for the
majority of healthy individuals drawn in the pedigrees.
However, in general, information on premature death had
been documented. Three oncologists and one genetic
counsellor had been involved in the family history
investigation.
In the present study, pedigrees were transformed into
text ﬁles that were uploaded for risk calculations according
to BOADICEA version 1 guidelines. Since information on
ages for healthy family members frequently was lacking,
the parameters ‘‘year of birth’’, ‘‘age’’ or ‘‘age at death’’
were set according to: (1) year of birth in agreement with
25 years between each generation and 2 years between
siblings. (2) 75 years as age at death. Spouses not drawn in
the pedigree but required for BOADICEA analyses were
consistently censored at age zero. If age at death for a
deceased individual with cancer (breast-, ovarian-, pros-
tate-, pancreatic-) was unknown, it was set to 2 years after
cancer diagnosis. When known, Jewish ancestry was
recorded in the text ﬁles prepared for BOADICEA.
The risk analyses were performed retrospectively during
2010 using BOADICEA version 1. The non optional values
of mutation frequencies were for BRCA1 0.0006394 and
for BRCA2 0.00102.
The present study did not cause any interventions in the
care of the included women. The risk calculations used
data about family history, incidence of breast cancer and
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the clinical routine and/or the PSDM.
Prediction of BRCA1 and BRCA2 mutations
The 652 available pedigrees included 288 mutation
screening results, documented before 1 September 2010.
The screened individual, for whom the mutation risks were
calculated, was most often not the index person in the
family but a close relative with breast or ovarian cancer.
When several individuals in the same family had been
screened, only the mutation risks of the ﬁrst screened
person were calculated and later gained information about
family history and screening events were not taken into
account. Twenty-ﬁve of the screening events were not
included due to difﬁculties in interpreting records of family
data at the date of screening (18), screened individual
common for two families (6), or screening of only one gene
(1). The remaining 263 individuals (representing 263 dis-
tinct families) were included, regardless of screening
result, for the retrospective calculation of mutation proba-
bilities prior to BRCA1 and BRCA2 mutation screening. All
included individuals were of Scandinavian origin except
for ﬁve with Iranian (1), Iraqi (1) and Ashkenazi Jewish (3)
ancestry respectively.
The screening events represented 246 analyses on fresh
material and 17 analyses on parafﬁn-embedded tissue.
Among the 246 analyses there were 25 analyses without
the MLPA technique. The sensitivities of the mutation
screening methods were taken into account when calcu-
lating the expected number of mutations. The sensitivities
were estimated to; 75% for analyses that were performed
on DNA from parafﬁn-embedded tissue; 80% for analyses
on DNA from fresh material prior to the introduction of the
MLPA technique; 90% for DNA analyses from fresh
material that included MLPA. The BRCA1 and BRCA2
mutation risks for all screened individuals were multiplied
with the corresponding mutation detection sensitivity. The
sum of the individual risks represented the expected
number of mutations.
Observed BRCA1 and BRCA2 mutations
Individuals were classiﬁed as BRCA1 or BRCA2 mutation
carriers if they carried a pathogenic mutation according to
internationally recognized criteria [16].
Prediction of breast cancer
The 652 pedigrees included eleven index persons with
ovarian cancer and one index person who underwent pro-
phylactic mastectomy before start of observation. Exclu-
sion of these twelve women resulted in 640 index persons
for whom breast cancer risk during observation period were
calculated. The 640 women represented 622 distinct fam-
ilies since there were 18 pairs of relatives (sisters/mother/
aunt). All 640 individuals were of Scandinavian origin
except for six with Iranian (1), Iraqi (1) or Ashkenazi
Jewish (5) ancestry respectively. Approximately one-ﬁfth
of all diagnoses included were unveriﬁed. In total 27
included index persons had had a ﬁrst breast cancer, all
invasive, prior to start of observation. Results of mutation
screening that were known prior to start of observation
were recorded in the text ﬁles for BOADICEA. The pre-set
values for mutation search sensitivities were 0.7 and 0.8 for
BRCA1 and BRCA2 respectively. These values were in
accordance with the estimated sensitivity of the mutation
screening techniques used until June 2006. There were 95
pedigrees that included a negative mutation analysis and
among the index persons there were 36 known mutation
carriers, 29 for BRCA1 and 7 for BRCA2. Among the 640
pedigrees 12 diagnoses were solely DCIS. These were also
included in the calculations.
The risk of a ﬁrst or contralateral breast cancer for each
index person during the observation period was calculated.
The date when the family history was summarized in the
medical records and the woman was offered annual breast
examinations was deﬁned as the start of the observation
period for each individual in the present study. Cancer
diagnoses or mutation screening for any family member
after that date were not included. The end of the observa-
tion period was deﬁned as the date of PM/death/migration/
1 September 2010, whichever took place ﬁrst. Each index
person’s risk was obtained from the BOADICEA result ﬁle
that lists annual risks for the ﬁrst 5 years, followed by risks
for every ﬁfth year. For periods equalling 6, 7, 8 or 9 years
the resulting risk was obtained as the sum of the 5-year risk
and the term ‘‘10-year risk minus 5-year risk, divided by 5,
multiplied by 1, 2, 3 or 4 respectively’’.
Subsequently the breast cancer risks for all index per-
sons during the observation period were summarized to
obtain the expected number of breast cancers within the
period.
Observed breast cancers at end of observation period
Information on all incidental breast cancer cases among the
index persons during the observation period was found in
medical records. Women no longer living in the catchment
area were checked for cancer status until 1 September 2010
in the Swedish Cancer Registry.
Statistical methods
The overall accuracy in terms of the expected number of
BRCA1 and BRCA2 mutation carriers, and of incidental
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calculating the ratio of the observed and expected number
of events. This ratio was presented together with its 95%
exact Poisson conﬁdence interval.
To evaluate the ability of the model—at individual
level—to distinguish between carrier and non-carrier, and
between those who would develop breast cancer and those
who would not, the area under the receiver operating
characteristic (ROC) curve was used. The larger the area
under the curve the better the test, with a value of 1 indi-
cating perfect discrimination and a value of 0.5 no better
than chance discrimination. The ROC analysis results are
presented as the area under the curve together with 95%
bootstrap conﬁdence intervals.
Results
Prediction of BRCA1 and BRCA2 mutations
The expected numbers of BRCA1-, BRCA2-, and BRCA
(1 or 2) mutations were 33, 21 and 54 respectively. The
observed numbers were 47 BRCA1- and 13 BRCA2 muta-
tions, altogether 60 BRCA(1 or 2) mutations. The ratios of
observed to expected numbers of mutations were 1.43, 0.63
and 1.12 for BRCA1-, BRCA2-, and BRCA(1 or 2)
respectively. The ratios demonstrated that the number of
BRCA2 mutations and the total number of BRCA1 and
BRCA2 mutations could be predicted by the model,
whereas the speciﬁc number of BRCA1 mutations was
signiﬁcantly underestimated (Table 1). There were 203
negatively screened samples, of these 25 had not yet been
supplemented with the MLPA method.
BOADICEA’sabilitytodiscriminatebetweencarriersand
non-carriersatindividuallevel asmeasured bythe areaunder
the ROC curve (AUC) was 0.86, 0.69 and 0.83 for BRCA1,
BRCA2 and BRCA(1 or 2) respectively (Table 1,F i g .1). All
ROC areas were signiﬁcantly different from 0.5.
The sensitivities and speciﬁcities corresponding to the
carrier probability cut-off points 4, 5, 10 and 15% ranged
from 98.3 to 81.7% and 34.0–72.4% respectively
(Table 2).
Prediction of breast cancer
The sum of all breast cancer risks during the observation
periods (in total 4,507 years), corresponding to the
expected number of breast cancers, was calculated for the
640 index persons. In total, 613 risk estimates corre-
sponded to a ﬁrst breast cancer and 27 to a contralateral
disease. The total number of expected breast cancers was
17.7.
The observed diagnoses among the 640 women during
the observation period were 25 invasive breast cancers and
ﬁve DCIS. Two DCIS cases were diagnosed at PM. The
ratio of ‘‘observed’’ to ‘‘expected’’ for invasive cancers was
1.41. When DCIS cases were included the corresponding
Table 1 Observed and expected numbers of BRCA1 and BRCA2 mutations in a subset of individuals (n = 263)
Observed (O) Expected (E) O/E (95% CI) ROC area (95% CI)
BRCA1 BRCA1 versus non-BRCA1
47 (2 P) 33 1.43 (1.05–1.90)* 0.86 (0.79–0.91)
BRCA2 BRCA2 versus non-BRCA2
13 (1 P) 21 0.63 (0.34–1.08) 0.69 (0.58–0.78)
BRCA(1 or 2) BRCA1 or BRCA2 versus non-carriers
60 (3 P) 54 1.12 (0.86–1.44) 0.83 (0.76–0.88)
Discrimination between carriers and non-carriers of mutations in BRCA1 and/or BRCA2 as measured by area under the ROC curve
P, analyses of parafﬁn embedded tissue. * Signiﬁcant deviation from 1
Fig. 1 ROC curve showing the discrimination between BRCA(1 or 2)
mutation carriers and non-carriers
Table 2 BRCA1/2 carrier probability thresholds and corresponding
sensitivity and speciﬁcity
Threshold, % Sensitivity, % (95% CI) Speciﬁcity, % (95% CI)
C 4 98.3 (91.1–100.0) 34.0 (27.5–41.0)
C 5 95.0 (86.1–99.0) 40.9 (34.1–48.0)
C 10 88.3 (77.4–95.2) 62.6 (55.5–69.2)
C 15 81.7 (69.6–90.5) 72.4 (65.7–78.4)
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123ratio was 1.69 (Table 3). The ratio did not deviate signif-
icantly from 1 if only invasive cancers were counted. In
contrast, when DCIS cases were included, the model sig-
niﬁcantly under predicted the breast cancer incidence.
The ability of the model to discriminate between indi-
viduals who had invasive breast cancer and those that did
not during the observation period as measured by AUC was
0.62 (Table 3, Fig. 2). When DCIS was accounted for
among the observed cases the corresponding areas was
0.63 (Table 3). Both ROC areas were signiﬁcantly different
from 0.5.
Discussion
The ability of BOADICEA to predict BRCA1
and BRCA2 mutations
The model’s ability to predict BRCA1 and BRCA2 muta-
tions has previously been investigated in several different
populations here exempliﬁed by 195 French-Canadian
families [9] and 1934 British families [10]. Both studies
demonstrated that BOADICEA was well calibrated at
group level, as reﬂected by ratios O/E *1. Regarding
discrimination between carriers and non-carriers, ROC
curve areas ranged from 0.77 to 0.81.
The present study evaluated BOADICEA by using
family data corresponding to the time of mutation screen-
ing. The model’s prediction of the total number of BRCA1
and BRCA2 mutations among the 263 individuals that had
been screened for mutations was close to the observed
number. This result indicated agreement between the data
used to develop the model and the total prevalence of
BRCA(1 or 2) mutations in our cohort. Further, the ability
to discriminate between carriers and non-carriers was
measured to an AUC of 0.83 which is similar to the
reported value for British families.
The model performed worse in predicting the respective
numbers of BRCA1 and BRCA2 mutations, which was to be
expected since its pre-set values corresponded to mutation
frequencies in the UK. In Sweden BRCA1 mutations are
more frequent than BRCA2 mutations due to several well-
known BRCA1-founder mutations [15], the opposite from
the situation in the UK. In BOADICEA version 2 the
parameter mutation frequency can be changed manually in
order to ﬁt a certain population.
All of the 263 individuals had met the clinical criteria
regarding family history for mutation screening. Applying
the present results in this group by setting screening
thresholds based on carrier probabilities demonstrated that
substantial proportions of mutation screening analyses with
a negative outcome can be avoided. At a threshold of 10%
carrier probability the model had 88.3% sensitivity and
62.6% speciﬁcity in the present study, but as a result seven
mutation carriers would not have been offered mutation
screening. For comparison, at the same threshold (10%),
BOADICEA had a sensitivity of 90.4% and a speciﬁcity of
39.5% when investigated in British families [10]. In our
cohort, we observed a sensitivity of 98.3% and a speciﬁcity
of 34.0% at a threshold of 4% carrier probability. As a
consequence, had mutation screening been offered only to
individuals with a carrier probability of at least 4%, a
quarter of all 263 individuals had not been screened for
mutations. Still we would have identiﬁed all but one of the
60 conﬁrmed carriers. We conclude that one missed
mutation carrier versus 69 saved screening analyses is an
acceptable trade-off.
The predictive ability may increase further in the next
version of BOADICEA, which is reported to include
tumour pathology data such as estrogen, progesterone and
HER2 receptor status, and the expression of ‘basal’
markers [17]. According to the model’s homepage, other
planned improvements are the addition of mutations in
other breast cancer susceptibility genes such as TP53,
ATM, CHEK2, PALB2, BRIP1, FGFR2, TNRC9 and
MAP3K1 [18].
Table 3 Observed and expected numbers of breast cancers
Observed
(O)
Expected
(E)
O/E (95% CI) ROC area
(95% CI)
Invasive BCs
25 E: 17.74 1.41 (0.91–2.08) 0.62 (0.52–0.73)
All BCs
a
30 E: 17.74 1.69 (1.14–2.41)* 0.63 (0.51–0.78)
Discrimination between individuals diagnosed with breast cancer and
individuals without diagnosis measured by area under the ROC curve
BC breast cancer.
a Including 5 DCIS. * Signiﬁcant deviation from 1
Fig. 2 ROC curve showing the discrimination between women
diagnosed with breast cancer and women without breast cancer
diagnosis
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BRCA1 and BRCA2 mutations was based on data that was
collected before BOADICEA was in use. Healthy indi-
viduals were included even if detailed information
regarding age was lacking (further discussed below). It is
possible that this approach inﬂuenced our results regarding
overall accuracy and discrimination.
The ability of BOADICEA to predict breast cancer
The present study calculated breast cancer risk for women
who at the start of observation were free from cancer.
Consequently, no woman was under treatment for breast
cancer at the start of observation, which would have
decreased the risk of a second breast cancer during
observation time. However, we did not account for
the reduction in breast cancer risk conferred by the pro-
phylactic salpingo-oophorectomy that 18 women had
undergone.
Although a slight underestimation was found, the breast
cancer prediction of 17.7 did not signiﬁcantly deviate from
the 25 observed invasive breast cancers. Similarly, the
Tyrer–Cuzick model was reported to predict the risk of
breast cancer in 1933 women, recruited from a family
history clinic and surveyed by annual mammography, with
the same degree of underestimation as BOADICEA’s in the
present study. It was also demonstrated that another model,
the Manual model, predicted more closely the observed
number of breast cancers in that subgroup of women,
whereas the Claus model (an algorithm that calculates
remaining risk as opposed to the Claus tables which give
lifetime risks) and BRCAPRO statistically signiﬁcantly
underestimated the risk [19].
There are factors that might have contributed to that the
estimated number of breast cancers were lower than the
observed. For example, the BRCA1 mutation frequency
found in the present cohort was higher than predicted by
the model. Since the average cumulative breast cancer risk
at younger ages is higher for BRCA1 than for BRCA2
mutation carriers, this discrepancy will result in an
underestimation of breast cancer risk [7]. In addition,
BOADICEA performed better in predicting BRCA1 and
BRCA2 mutations when larger pedigrees were used [9]
although including uncertain data made the model perform
worse [10]. When we calculated breast cancer risks with
BOADICEA, the effects of including healthy family
members became obvious. The average individual lifetime
risk decreased from 24.9 to 23.1%, a reduction of 7%,
when year of birth and life length were assessed for healthy
family members. The information collected at the start of
the observation period regarding healthy family members
would have been more detailed if BOADICEA guidelines
had been in use at that time. Nevertheless, information of
putative premature death among family members without
any of the cancer diagnoses relevant for BOADICEA was
routinely collected. Therefore we believe that the occa-
sional underestimation of risk as a result of assigning
longer lives to individuals who died prematurely would be
smaller than the corresponding overestimation of risk if all
healthy individuals that lacked detailed birth and death data
had been censored at age zero. A person was censored at
age zero if lack of knowledge was indicated in the pedi-
gree. Likewise, we chose to censor a deceased individual
with a relevant cancer diagnosis by setting death to 2 years
after diagnosis unless date of death was known. This is a
minor deviation from BOADICEA version 1 guidelines
that suggest that deceased individuals with cancer diag-
nosis and unknown date of death should be censored at the
age of cancer diagnosis.
Finally, 96% of the women had annual breast examin-
ations, 3% had mammography every second year and 1%
were not monitored due to migration or death. Intensive
surveillance and breast cancer diagnosis at PM confer a
lead time bias that contributes to a higher number of
observed than expected invasive breast cancers and to the
signiﬁcant underestimation of breast cancer when DCIS are
included among the observed cases. It has been suggested
that the incidence of DCIS can be adjusted by adding
10 years to age at diagnosis, assuming that the DCIS would
have become invasive during that time [20]. If so, none of
‘our’ ﬁve observed DCIS would have been accounted for,
since observation periods were shorter than 10 years. The
demonstrated underestimation of breast cancer risk when
DCIS was included among observed breast cancers is in
accordance with that the model was developed for invasive
breast cancers, not DCIS.
The ability of BOADICEA to distinguish individuals
who were diagnosed with breast cancer (invasive or DCIS)
from those who were not—on the basis of each individual’s
risk for the observation period—was investigated. An AUC
of 0.63 indicated a clinical usefulness. This value was
lower than the corresponding values reported for the Gail
(0.74), Claus (0.72), Ford (0.74) and Tyrer–Cuzick (0.76)
risk assessment methods, which were evaluated in a British
cohort [19].
In Swedish oncogenetic clinics there are ongoing dis-
cussions regarding at what breast cancer risk level sur-
veillance beyond general mammography screening should
be offered. It has been suggested that a life time risk of
20% according to BOADICEA should indicate follow-up
and that a life time risk of 17–19.9% should lead to an
individualized assessment. In the present cohort BOADI-
CEA was used to retrospectively calculate life time risks
(20–80 years). It was demonstrated that the proportion of
breast cancer in the groups with\17% and 17–19.9% life
time risk was 1.8 and 5.4% respectively, compared to 6.7%
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The corresponding age-adjusted risk in Swedish women in
general with a life time risk of 10% [21], was 0.9%, or 5.5
breast cancer cases. Four of the observed breast cancers
were diagnosed in women with a life time breast cancer
risk of less than 17%.
Taken together, the estimated background risk and the
observed high incidence of breast cancer cases in women
with 17–19.9% life time risk indicate that a cut-off point of
17% for follow-up could be considered.
As opposed to life time risk, each woman’s risk for the
observation period depended on her age at start of obser-
vation. To identify an alternative cut-off point for follow-
up, based on the risks for the observation periods, we
needed to compensate for that the observation period
length differed between individuals. Therefore, an annual
risk was calculated for all index persons by dividing each
risk for the observation period by the corresponding
number of years. Here, we allowed the observation period
to be uninterrupted by PM/death/migration in order to
mimic a counselling situation at the clinic. An analysis of
the annual risk score regarding discrimination between
breast cancer and no breast cancer resulted in an AUC of
0.68. If an annual risk score of 0.3% had been used as cut-
off point for breast cancer preventive measures in the
present study, the numbers of breast cancers in the group
below the threshold would have been ﬁve, similar to the
estimated background risk. The distribution of observed
breast cancers, including DCIS, over four intervals of
annual risk is shown in Fig. 3 and the number of women
per interval in Table 4. It was demonstrated that with a cut-
off point of 0.3% annual risk 210 women would not have
been offered follow-up at the time of risk assessment. An
annual risk level of 0.33% coincides with a ﬁve-year risk of
1.67% (as estimated by the Gail model 2 [22]) which is
accepted by the US Food and Drug Administration as a cut-
off point for segregating high- and low-risk individuals
[23].
Contralateral breast cancer and ovarian cancer
There were four cases of contralateral disease among the
25 invasive breast cancers. Due to the small sample size
statistical analyses of the ability of BOADICEA to predict
contralateral breast cancer were not presented. Likewise,
the model’s ability to predict ovarian cancer could not be
evaluated since 18 of the 36 women that were known
BRCA1 or BRCA2 mutation carriers at the start of obser-
vation underwent salpingo-oophorectomy prior to or during
the observation period. Among the 36 known carriers, the
predicted number of ovarian cancers was 1.3. No ovarian
cancer was observed in the study population.
Summary
The ﬁndings in the present study population support that
individuals with a mutation probability of 4%, as calcu-
lated by BOADICEA, could be offered mutation screening.
In addition, a threshold of 17% life time risk or 1.67% ﬁve-
year risk could be considered for increased breast
surveillance.
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percentage of breast cancer incidence in each category
Table 4 Numbers of individuals and observed breast cancers per
interval of annual risk
Breast cancer Annual risk % Total
\0.31 0.31–0.49 0.50–0.74 C0.75
No 210 254 91 55 610
Yes 5 11 7 7 30
Total 215 265 98 62 640
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